METHOD FOR INHIBITING SIGNALING MEDIATED BY ErbB2, SIGNALING INHIBITOR TO BE USED THEREFOR AND USE THEREOF

A signaling inhibitor inhibiting activation of signaling pathway, wherein:

• said signaling pathway is mediated by ErbB2 in a human cell;
• said inhibitor comprises a nucleic acid;
• said nucleic acid is at least one nucleic acid selected from the group consisted of the following (a1), (a2), (b1) and (b2):
• (a1):
• a nucleic acid comprising a nucleotide sequence comprising the 1st-the 555th region of the nucleotide sequence shown in SEQ ID NO:
• 2;
• (a2):
• a nucleic acid comprising a nucleotide sequence in which one or several nucleotides are deleted, replaced or added in said (a1), and encoding for a polypeptide having a function equivalent to PTB domain of human FRS2β;
• (b1):
• a nucleic acid comprising a nucleotide sequence comprising the 709th-the 756th region of the nucleotide sequence shown in SEQ ID NO:
• 2;
• (b2):
• a nucleic acid comprising a nucleotide sequence in which one or several nucleotides are deleted, replaced or added in said (b1), and encoding for a polypeptide having a function of binding with human ERK2;
• and
• said nucleic acid expresses a coded polypeptide in the cell.

A signaling inhibitor inhibiting activation of signaling pathway, wherein:

• said signaling pathway is mediated by ErbB2 in a human cell;
• said inhibitor comprises a polypeptide;
• said polypeptide is at least one polypeptide selected from the group consisted of the following (A1), (A2), (B1) and (B2):
• (A1):
• a polypeptide comprising an amino acid sequence comprising the 1st-the 185th region in the amino acid sequence shown in SEQ ID NO:
• 1;
• (A2):
• a polypeptide comprising an amino acid sequence in which one or several amino acid residues are deleted, replaced or added in said (A1), and having a function equivalent to PTB domain of human FRS2β;
• (B1):
• a polypeptide comprising an amino acid sequence comprising the 232nd-the 252nd and the 237th-the 252nd region in the amino acid sequence shown in SEQ ID NO:
• 1;
• and
• (B2):
• a polypeptide comprising an amino acid sequence in which one or several amino acid residues are deleted, replaced or added in said (B1), and having a function of binding with human ERK2.

Use of at least one nucleic acid selected from the group consisted of the following (a1), (a2), (b1) and (b2) for inhibiting activation of signaling pathway mediated by ErbB2 in a human cell:

• (a1):
• a nucleic acid consisted of a nucleotide sequence comprising the 1st-the 555th region of the nucleotide sequence shown in SEQ ID NO:
• 2;
• (a2):
• a nucleic acid consisted of the nucleotide sequence in which one or several nucleotides are deleted, replaced or added in said (a1), and encoding for a polypeptide having function equivalent to PTB domain of human FRS2β;
• (b1):
• a nucleic acid consisted of a nucleotide sequence comprising the 709th-the 756th region of the nucleotide sequence shown in SEQ ID NO:
• 2;
• and
• (b2):
• a nucleic acid consisted of the nucleotide sequence in which one or several nucleotides are deleted, replaced or added in said (b1), and encoding for a polypeptide having a function of binding with human ERK2.

Use of at least one nucleic acid selected from the group consisted of the following (a1), (a2), (b1) and (b2) for treating human cancer:

• (a1):
• a nucleic acid consisted of a nucleotide sequence comprising the 1st-the 555th region of the nucleotide sequence shown in SEQ ID NO:
• 2;
• (a2):
• a nucleic acid consisted of the nucleotide sequence in which one or several nucleotides are deleted, replaced or added in said (a1), and encoding for a polypeptide having function equivalent to PTB domain of human FRS2β;
• (b1):
• a nucleic acid consisted of a nucleotide sequence comprising the 709th-the 756th region of the nucleotide sequence shown in SEQ ID NO:
• 2;
• and
• (b2):
• a nucleic acid consisted of the nucleotide sequence in which one or several nucleotides are deleted, replaced or added in said (b1), and encoding for a polypeptide having a function of binding with human ERK2.

Use of at least one polypeptide selected from the group consisted of the following (A1), (A2), (B1) and (B2) for inhibiting the activation of signaling pathway mediated by ErbB2 in a human cell:

• (A1):
• a polypeptide consisted of an amino acid sequence comprising the 1-the 185th region of the amino acid sequence shown in SEQ ID NO:
• 1;
• (A2):
• a polypeptide consisted of the amino acid sequence in which one or several amino acids are deleted, replaced or added in said (A1), and a polypeptide having function equivalent to PTB domain of human FRS2β;
• (B1):
• a polypeptide consisted of an amino acid sequence comprising the 232nd-the 252nd and the 237th-the 252nd region of the amino acid sequence shown in SEQ ID NO:
• 1;
• and
• (B2) a polypeptide consisted of the amino acid sequence in which one or several amino acids are deleted, replaced or added in said (B1), and a polypeptide having a function of binding with human ERK2.

Use of at least one polypeptide selected from the group consisted of the following (A1), (A2), (B1) and (B2) for treating human cancer:

• (A1):
• a polypeptide consisted of an amino acid sequence comprising the 1st-the 185th region of the amino acid sequence shown in SEQ ID NO:
• 1;
• (A2):
• a polypeptide consisted of the amino acid sequence in which one or several amino acids are deleted, replaced or added in said (A1), and a polypeptide having function equivalent to PTB domain of human FRS2β;
• (B1):
• a polypeptide consisted of an amino acid sequence comprising the 232nd-the 252nd and the 237th-the 252nd region of the amino acid sequence shown in SEQ ID NO:
• 1;
• and
• (B2):
• a polypeptide consisted of the amino acid sequence in which one or several amino acids are deleted, replaced or added in said (B1), and a polypeptide having a function of binding with human ERK2.